Silgard, a treatment for cervical cancer
We are searching data for your request:
Upon completion, a link will appear to access the found materials.
Silgard, the tetravalent recombinant vaccine against human papilloma virus (HPV), the first and only product of its kind in the world, is now available in Romania. Produced by Merck Sharp & Dohme (MSD), Silgard is the only vaccine that prevents cervical cancer, precancerous lesions, genital warts and other conditions caused by the 4 types of HPV (6, 11, 16 and 18).
Recognized as an innovation in world medicine and approved by the European Commission in just nine months, Silgard can be administered to children between 9 and 15 years old and young women between the ages of 16 and 26 years. The vaccination scheme comprises 3 injections administered over 6 months (0, 2, 6 months). Silgard is available in pharmacies throughout the country and can be issued only on prescription, at the recommendation of family doctors or specialists (gynecologists, pediatricians and infectionsists).
Clinical studies and tests have shown that Silgard 100% prevents cervical cancer and other HPV 6, 11, 16 and 18, when given to people who have not been infected with these types of viruses. before vaccination. Depending on the doctor's advice and the results of the Pap test, the vaccine can be recommended to any woman.
In Europe, approximately 33,500 women are diagnosed and 15,000 women die annually from cervical cancer (40 daily). Romania has one of the highest incidence rates in Europe (20-30 new cases / 100,000 women), a situation similar to that of underdeveloped countries in Africa, Asia and South America.
In Romania, cervical cancer kills 5 women every day. Our country ranks first in Europe in terms of cervical cancer mortality. This is the second cause of cancer mortality in women in Romania (after breast cancer) and the first cause of death in young women (25 - 44 years old).
Worrying is that the mortality rate from cervical cancer in Romania is constantly increasing, from 15.68 cases / 100,000 women in 1982, to 31.5 cases / 100,000 women in 2000. The figures raised by Mortality from cervical cancer, which is registered in Romania, is due primarily to the late diagnosis of the disease (most patients are diagnosed with invasive cancer). According to the World Health Organization, the mortality rate due to cervical cancer in Romania is 2-2,7 times higher than in most countries of Central and Eastern Europe and 6.3 times higher than the average of the EU countries.
Silgard prevents most HPV disease types 6, 11, 16 and 18. HPV types 16 and 18 are responsible for about 70% of cervical cancer cases. HPV types 6 and 11 are the cause of about 90% of cases of genital warts. These four types of HPV are also responsible for approximately 35-50% of low-risk cervical, vaginal, and vulvar lesions and for abnormal Pap smear results.
MSD is currently conducting clinical trials to evaluate the potential of the Silgard vaccine and other HPV types, such as 31 and 45, which are responsible for approximately 9% of cervical cancer cases.
Clinical studies that have evaluated the immunogenicity of Silgard in men have shown that the immune responses to this vaccine in boys between the ages of 9 and 15 years are comparable to those of women between the ages of 16 and 26.
Silgard is currently available in over 50 countries around the world, including the US, European Union, Canada, Mexico, Brazil, Australia, Taiwan and New Zealand. In addition, registration applications were filed in about 50 other countries.